UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-Q

☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended ~~July~~October 31, 2025

☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from __________ to __________

Commission File Number: 333-218733

Yijia Group Corp.

(Exact name of registrant as specified in its charter)

Nevada	35-2583762
(State or Other Jurisdiction of Incorporation or Organization)	(IRS Employer Identification Number)

39 E Broadway, Suite 603, New York, NY	10002
(Address of principal executive offices)	(Zip Code)

Tel: +1-516-886-8888

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Name of each exchange on which registered
N/A	N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of ” large accelerated filer “, “accelerated filer”, “non-accelerated filer”, “emerging growth company” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☒

Emerging growth company ☐

Smaller reporting company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of the issuer’s common stock issued and outstanding was 25,012,270, as of ~~September~~December 1215, 2025.

QUARTERLY REPORT ON FORM 10-Q

TABLE OF CONTENTS

		Page
PART I	FINANCIAL INFORMATION:
Item 1.	Financial Statements	3
	Unaudited Condensed Consolidated Balance Sheets as of July 31, 2025 and April 30, 2025	4
	Unaudited Condensed Consolidated Balance Sheets as of October 31, 2025 and April 30, 2025	4
	Unaudited Condensed Consolidated Statements of Operations for the Three Months ended July 31, 2025 and 2024	5
	Unaudited Condensed Consolidated Statements of Operations for the Three and Six Months ended October 31, 2025 and 2024	5
	Unaudited Condensed Consolidated Statements of Changes in Shareholders’ Equity for the Three Months Ended July 31, 2025 and 2024	6
	Unaudited Condensed Consolidated Statements of Changes in Shareholders’ Equity for the Three and Six Months Ended October 31, 2025 and 2024	6
	Unaudited Condensed Consolidated Statements of Cash Flows for the Three Months ended July 31, 2025 and 2024	7
	Unaudited Condensed Consolidated Statements of Cash Flows for the Six Months ended October 31, 2025 and 2024	7
	Notes to the Unaudited Condensed Consolidated Financial Statements	8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1620
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	2127
Item 4.	Controls and Procedures	2127
PART II	OTHER INFORMATION:
Item 1.	Legal Proceedings	2228
Item 1A	Risk Factors	2228
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	2228
Item 3.	Defaults Upon Senior Securities	2228
Item 4.	Mine Safety Disclosures	2228
Item 5.	Other Information	2228
Item 6.	Exhibits	2228
Signatures		2329

PART 1I – FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

The accompanying interim consolidated financial statements of Yijia Group Corp. (“the Company”, “we”, “us” or “our”) have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with United States generally accepted principles have been condensed or omitted pursuant to such rules and regulations.

The interim consolidated financial statements are condensed and should be read in conjunction with the Company’s latest annual consolidated financial statements.

In the opinion of management, the consolidated financial statements contain all material adjustments, consisting only of normal adjustments considered necessary to present fairly the financial condition, results of operations, and cash flows of the Company for the interim periods presented.

YIJIA GROUP CORP.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

	July 31, 2025		April 30, 2025
	October 31, 2025		April 30, 2025
	(Unaudited)
ASSETS
Current assets:
Cash	$	1,~~046~~259,~~620~~281	$	782,810
Accounts receivable		1882,~~014,282~~612		1,266,951
Advances to vendors		~~158~~172,~~802~~310		158,802
Prepayment		107,~~083~~333		–
Inventories		911,~~130~~267		44,247
Other current assets		3,441		3,441
Total current assets		2,~~242~~336,~~358~~244		2,256,251
TOTAL ASSETS	$	2,~~242~~336,~~358~~244	$	2,256,251
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities:
Accounts payable and accrued expenses	$	67,431	$	60,065
Accrued expenses	$	68,713	$	60,065
Deferred revenue		10,775		–
Accounts payable		168,450		–
Other current liabilities		1,226		820
Deferred revenue		4,286		–
Income tax payable		300,543		286,682
Other current liabilities		3,951		820
Total current liabilities		379,975		347,567
Income tax payable		192,651		286,682
TOTAL LIABILITIES		379,975		347,567
Total current liabilities		438,051		347,567
TOTAL LIABILITIES		438,051		347,567
Commitments and Contingencies		–		–
Shareholders’ equity:
Common Stock, $0.001 par value; 75,000,000 shares authorized; 25,012,270 shares issued and outstanding as of July 31, 2025 and April 30, 2025		25,012		25,012
Common Stock, $0.001 par value; 75,000,000 shares authorized; 25,012,270 shares issued and outstanding as of October 31, 2025 and April 30, 2025		25,012		25,012
Additional paid in capital		1,012,971		1,012,971
Shares to be issued – 50,000 shares of common stock		3,000		3,000
Retained earnings		~~821~~857,~~400~~210		867,701
Total Shareholders’ Equity		1,~~862~~898,~~383~~193		1,908,684
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	2,~~242~~336,~~358~~244	$	2,256,251

The accompanying notes are an integral part of these interim unaudited consolidated financial statements.

YIJIA GROUP CORP.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND ~~THREE~~SIX MONTHS ENDED ~~JULY~~OCTOBER 31, ~~2025~~ 2025 AND 2024 (UNAUDITED)

	Three Months ended July 31,
	Three months ended October 31,						Six months ended October 31,
	2025			2024			2025			2024
Revenue, net	$	~~103~~427,~~899~~115		$	~~108~~292,~~477~~118		$	531,014		$	400,595
Cost of revenue		(35166,~~118~~312	)		(35136,~~304~~284	)		(201,430	)		(171,588	)
Gross profit		68260,~~781~~803			73155,~~173~~834			329,584			229,007
Operating expenses
Sales and distribution expenses		–(2,900	)		(~~7,030~~159	)		(2,900	)		(7,189	)
Personnel and benefit costs		(3439,~~928~~289	)		(5352,~~984~~968	)		(74,216	)		(106,952	)
General and administrative expenses		(66119,~~293~~444	)		(5740,~~573~~107	)		(185,738	)		(97,680	)
Total operating expenses		(~~101~~161,~~221~~633	)		(~~118~~93,~~587~~234	)		(262,854	)		(211,821	)
Loss before income tax		(32,440	)		(45,414	)
Income from operations		99,170			62,600			66,730			17,186
Income tax expense		(13,861	)		(9,797	)
Other income (expense):
Net loss	$	(46,301	)	$	(55,211	)
Other income		120			300			120			300
Loss per share, basic and diluted	$	(0.00	)	$	(0.00	)
Interest expenses		–			(2,125	)		–			(2,125	)
Weighted average number of shares outstanding, basic and diluted		25,012,270			25,012,270
Total other expense, net		120			(1,825	)		120			(1,825	)
Income before income tax		99,290			60,775			66,850			15,361
Income tax expense		(63,480	)		(28,128	)		(77,341	)		(37,925	)
Net income (loss)	$	35,810		$	32,647		$	(10,491	)	$	(22,564	)
Income (loss) per share, basic and diluted	$	0.00		$	0.00		$	(0.00	)	$	(0.00	)
Weighted average number of shares outstanding, basic and diluted		25,012,270			25,012,270			25,012,270			25,012,270

The accompanying notes are an integral part of these interim unaudited consolidated financial statements.

YIJIA GROUP CORP.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (DEFICIT)

FOR THE ~~THREE~~SIX MONTHS ENDED ~~JULY~~OCTOBER 31, 2025 AND ~~2024~~ 2024 (UNAUDITED)

	Common Stock
	No. of shares		Amount		Additional paid-in capital		Shares to be issued		Retained earnings (accumulated deficit)			Total shareholders’ equity ~~(deficit)~~
Balance as of May 1, 2025		25,012,270	$	25,012	$	1,012,971	$	3,000	$	867,701		$	1,908,684
Net loss for the period		–		–		–		–		(46,301	)		(46,301	)
Balance as of July 31, 2025		25,012,270	$	25,012	$	1,012,971	$	3,000	$	821,400		$	1,862,383
Net income for the period		–		–		–		–		35,810			35,810
Balance as of October 31, 2025		25,012,270	$	25,012	$	1,012,971	$	3,000	$	857,210		$	1,898,193
Balance as of May 1, 2024		25,012,270	$	25,012	$	1,012,971	$	1,000	$	16,955		$	1,055,938
Share-based compensation – 15,000 shares		–		–		–		750		–			750
Net loss for the period		–		–		–		–		(55,211	)		(55,211	)
Balance as of July 31, 2024		25,012,270	$	25,012	$	1,012,971	$	1,750	$	(38,256	)	$	1,001,477
Share-based compensation – 15,000 shares		–		–		–		750		–			750
Net income for the period		–		–		–		–		32,647			32,647
Balance as of October 31, 2024		25,012,270	$	25,012	$	1,012,971	$	2,500	$	(5,609	)	$	1,034,874

The accompanying notes are an integral part of these interim unaudited consolidated financial statements.

YIJIA GROUP CORP.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE ~~THREE~~SIX MONTHS ENDED ~~JULY~~OCTOBER 31, 2025 AND ~~2024~~ 2024 (UNAUDITED)

	Three months ended July 31,
	Six months ended October 31,
	2025			2024
Cash flows from operating activities:
Net loss	$	(4610,~~301~~491	)	$	(5522,~~211~~564	)
Adjustment to reconcile net loss used in operating activities:
Adjustment to reconcile net income (loss) used in operating activities:
Share-based compensation		–			750
Interest expenses		–			2,125
Share-based compensation		–			1,500
Changes in operating assets and liabilities:
Inventories		3532,~~118~~980			(80170,~~590~~221	)
Accounts receivable		~~252~~384,~~669~~339			–(57,700	)
Advances to vendors		–(13,508	)		(~~379~~210,~~392~~912	)
Prepayment		(107,~~083~~333	)		–
Other current assets		–			~~588~~2,638
Accounts payable and accrued liabilities		7,366			6,500
Accrued liabilities		8,648			6,501
Deferred revenue		10,775			–
Accounts payable		168,450			–
Other current liabilities		406			(6,443	)
Deferred revenue		4,286			–
Income tax payable		13,861			9,797
Other current liabilities		3,131			(7,400	)
Net cash provided by (used in) operating activities		263,810			(504,001	)
Income tax payable		(94,031	)		(39,208	)
Cash flows from financing activities:
Net cash provided by (used in) operating activities		476,471			(495,241	)
Proceeds from a related party		–			52,600
Cash flows from financing activity:
Net cash provided by financing activities		–			52,600
Proceeds from a related party		–			125,000
Net change in cash		263,810			(451,401	)
Net cash provided by financing activity		–			125,000
Net change in cash		476,471			(370,241	)
Cash, beginning of period		782,810			593,036
Cash, end of period	$	1,~~046~~259,~~620~~281		$	~~141~~222,~~635~~795
SUPPLEMENTAL CASH FLOW INFORMATION:
Interest paid	$	–		$	–
Income taxes paid	$	–94,031		$	–9,797

The accompanying notes are an integral part of these interim unaudited consolidated financial statements.

YIJIA GROUP CORP.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS

Yijia Group Corp. (“the Company” or “YJGJ”) was incorporated on January 25, 2017 under the laws of the State of Nevada, United States of America, formerly known as Soldino Group Corp.

The Company has currently commenced its ~~operation~~ operation in the rendering of consulting advisory services in management business, accounting and finance services; and provides dietary ~~healthcare~~supplement products and health consultation services to domestic and international customers. ~~The details of the Company’s subsidiary are described below:~~

Schedule of details of company subsidiary
Name	Place of incorporation and kind of legal entity	Principal activities and place of operation	Particulars of issued/ registered share capital	Effective interest Held
Nutripeak Trading Corporation (“NTC”)	State of Nevada, United States of America, Corporation	Marketing and supplying healthcare products	100 shares of common stock, par value $1 per share	100%

The details of the Company’s subsidiary are described below:

YJGJ and its subsidiary are hereinafter referred to as (the “Company”).


Name	Place of incorporation and kind of legal entity	Principal activities and place of operation	Particulars of issued/ registered share capital	Effective interest Held

NutriPeak Trading Corporation (“NTC”)	State of Nevada, United States of America, Corporation	Marketing and supplying dietary supplement products	100 shares of common stock, par value $1 per share	100%

YJGJ and its subsidiary are hereinafter referred to as the “Company”.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared by management in accordance with both accounting principles generally accepted in the United States (“GAAP”), and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Certain information and note disclosures normally included in audited consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. The unaudited condensed consolidated financial statements are presented in US dollars, which is the Company’s functional currency.

In the opinion of management, the condensed balance sheet as of April 30, 2025 which has been derived from audited consolidated financial statements and these unaudited condensed consolidated financial statements reflect all normal and considered necessary to state fairly the results for the periods presented. The results for the period ended ~~July~~October 31, 2025 are not necessarily indicative of the results to be expected for the entire fiscal year ending April 30, 2026 or for any future period.

These unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the Management’s Discussion and the audited consolidated financial statements and notes thereto included in the Annual Report on Form 10-K for the year ended April 30, 2025, filed with the SEC on July 24, 2025.

Principles of Consolidation

The unaudited condensed consolidated financial statements include the financial statements of the Company and its subsidiary. All significant inter-company balances and transactions within the Company have been eliminated upon consolidation.

Reclassifications

Certain amounts on the prior year’s unaudited condensed consolidated balance sheets, unaudited condensed consolidated statements of operations and cash flows were reclassified to conform to current-year presentation, with no effect on ending stockholders’ equity.

Use of Estimates and Assumptions

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Significant areas for which management uses estimates include:

	·	sales returns at point in time and allowances;
	·	inventory;
	·	income tax valuation allowances

These estimates require the use of judgment as future events, and the effect of these events cannot be predicted with certainty. The estimates will change as new events occur, as more experience is acquired and as more information is obtained. We evaluate and update our assumptions and estimates on an ongoing basis and we may consult outside experts to assist as considered necessary.

Revenue Recognition

	·	identify the contract with a customer;
	·	identify the performance obligations in the contract;
	·	determine the transaction price;
	·	allocate the transaction price to performance obligations in the contract; and
	·	recognize revenue as the performance obligation is satisfied.

Currently, the Company operates in two business segments.

The Consulting Service Segment mainly provides consulting advisory services in management, business, accounting and finance; and the ~~Healthcare Segment~~dietary ~~mainly~~supplement ~~provides healthcare~~ products and health consultation services to customers.

The sale and distribution of ~~healthcare~~dietary supplement products, such as Nicotinamide Riboside capsules, has only one performance obligation under the fixed-fee arrangements. Revenue is recognized ~~from~~ from the sale of their ~~healthcare~~dietary supplement products upon delivery to the customers, whereas the title and risk of loss are fully transferred to customers.

Shipping term under Ex Works (“EXW”), the Company fulfills the obligation to deliver when the products are available on their premises, i.e. the warehouse. Customers are responsible for all transportation costs, risk of loss, and any other costs that point onward.

Revenue is earned from the rendering of consulting advisory services to customers. The Company recognizes services revenue over the period in which such services are performed and billed to the customer, pursuant to the fulfillment of service terms in the agreement.

Disaggregation of Revenue

The following table provides information about disaggregated revenue from customers into the nature of the products and services provided, and the related timing of revenue recognition:

Schedule of disaggregated revenue
		Three Months ended July 31,
		For the three months ended October 31,				For the six months ended October 31,
Type of products or services	Timing of revenue recognition	2025		2024		2025		2024
Consultancy service fee income	Services transferred over time	$	46,~~225~~489	$	–3,838	$	10,714	$	3,838
Sales of healthcare products	Goods transferred at a point in time		99,674		108,477
Sales of dietary supplement products	Goods transferred at a point in time		420,626		288,280		520,300		396,757
Total		$	~~103~~427,~~899~~115	$	~~108~~292,~~477~~118	$	531,014	$	400,595

Recent Accounting Standard Adopted

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amended guidance requires incremental reportable segment disclosures, primarily about significant segment expenses. The amendments also require entities with a single reportable segment to provide all disclosures required by these amendments, and all existing segment disclosures. The amendments will be applied retrospectively to all prior periods presented in the financial statements and is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted this amended guidance on May 1, 2025 and concluded there is no significant impact on the footnotes to its consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amended guidance enhances income tax disclosures primarily related to the effective tax rate reconciliation and income taxes paid information. This guidance requires disclosure of specific categories in the effective tax rate reconciliation and further information on reconciling items meeting a quantitative threshold. In addition, the amended guidance requires disaggregating income taxes paid (net of refunds received) by federal, state, and foreign taxes. It also requires disaggregating individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received). The amended guidance is effective for fiscal years beginning after December 15, 2024. The guidance can be applied either prospectively or retrospectively. The Company adopted the amended guidance on May 1, 2025 and concluded there was no impact on its consolidated financial statements.

Accounting Standards Issued but Not Yet Adopted

In November 2024, the FASB issued ASU No. 2024-03, Disaggregation of Income Statement Expenses (“ASU 2024 03”), and in January 2025, the FASB issued ASU No. 2025-01, Clarifying the Effective Date (“ASU 2025-01”). The amendments are intended to enhance disclosures regarding an entity’s costs and expenses by requiring additional disaggregated information disclosures about certain income statement expense line items. The amendments, as clarified by ASU 2025-01, are effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the effect of adopting the new disclosure requirements.

Except for the above-mentioned pronouncements, there are no new recently issued accounting standards that will have a material impact on the unaudited condensed consolidated balance sheets, statements of operations and cash flows.

NOTE 3 — SEGMENT REPORTING

Currently, the Company has two reportable business segments:

(i) Consulting Service Segment, mainly provides consulting advisory services in management business, accounting and financial services; and (ii) ~~Healthcare~~Dietary supplement Segment, mainly provides ~~healthcare~~dietary ~~products~~supplement ~~to customers, most of them are distributors~~products.

In the following table, revenue is disaggregated by primary major product line, including a reconciliation of the disaggregated revenue with the reportable segments.

Schedule of reconciliation of the disaggregated revenues
	Three Months ended July 31, 2025
	Three Months ended October 31, 2025
	Healthcare Segment			Consulting Service Segment			Total
	Dietary Supplement Segment			Consulting Service Segment			Total
Revenue from external customers:
Consulting service income	$	–		$	46,~~225~~489		$	46,~~225~~489
Sale of healthcare products		99,674			–			99,674
Sale of dietary supplement products		420,626			–			420,626
Total revenue		99420,~~674~~626			~~4,225~~			~~103~~427,~~899~~115
Cost of revenue:
Consulting service income		–			–			–
Sale of healthcare products		(35,118	)		–			(35,118	)
Sale of dietary supplement products		(166,312	)		–			(166,312	)
Total cost of revenue		(35166,~~118~~312	)		–			(35166,~~118~~312	)
Gross profit		64254,~~556~~314			46,~~225~~489			68260,~~781~~803
Operating Expenses
Personal and benefit costs		(11,740	)		(23,188	)		(34,928	)
Sales and distribution expenses		(2,900	)		–			(2,900	)
General and administrative		(2,414	)		(63,879	)		(66,293	)
Personal and benefit costs		(11,739	)		(27,549	)		(39,289	)
Total operating expenses		(14,154	)		(87,067	)		(101,221	)
General and administrative		(7,546	)		(111,899	)		(119,444	)
Segment income (loss)	$	50,402		$	(82,842	)	$	(32,440	)
Total operating expenses		(22,185	)		(139,448	)		(161,633	)
Segment income (loss)	$	232,129		$	(132,959	)	$	99,170

Three Months ended July 31, 2024

Six Months ended October 31, 2025

Healthcare Segment

Consulting Service Segment

Total

Dietary Supplement Segment

Consulting Service Segment

Total

Revenue from external customers:

Consulting service income

–

–10,714

Sale of healthcare products

108,477

–

108,477

Sale of dietary supplement products

520,300

–

520,300

Total revenue

~~108~~520,~~477~~300

–10,714

~~108~~531,~~477~~014

Cost of revenue:

Consulting service income

–

Sale of healthcare products

(35,304

)

–

(35,304

)

Sale of dietary supplement products

(201,430

)

–

(201,430

)

Total cost of revenue

(35201,~~304~~430

)

–

(35201,~~304~~430

)

Gross profit

73318,~~173~~870

–10,714

73329,~~173~~584

Operating Expenses

Selling and distribution

(7,030

)

–

(7,030

)

Sales and distribution expenses

(2,900

)

–

(2,900

)

Personal and benefit costs

(1823,~~739~~479

)

(3550,~~245~~737

)

(5374,~~984~~216

)

General and administrative

(~~751~~9,960

)

(56175,~~822~~778

)

(57185,~~573~~738

)

Total operating expenses

(2636,~~520~~339

)

(92226,~~067~~515

)

(~~118~~262,~~587~~854

)

Segment income (loss)

46282,~~653~~531

(92215,~~067~~801

)

~~(45~~66,~~414~~730

)


	Three Months ended October 31, 2024
	Dietary Supplement Segment			Consulting Service Segment			Total
Revenue from external customers:
Consulting service income	$	–		$	3,838		$	3,838
Sale of dietary supplement products		288,280			–			288,280
Total revenue		288,280			3,838			292,118

Cost of revenue:
Consulting service income		–			–			–
Sale of dietary supplement products		(136,284	)		–			(136,284	)
Total cost of revenue		(136,284	)		–			(136,284	)

Gross profit		151,996			3,838			155,834

Operating Expenses
Selling and distribution		(159	)		–			(159	)
Personal and benefit costs		(17,723	)		(35,245	)		(52,968	)
General and administrative		(12,216	)		(27,891	)		(40,107	)
Total operating expenses		(30,098	)		(63,136	)		(93,234	)

Segment income (loss)	$	121,898		$	(59,298	)	$	62,600


	Six Months ended October 31, 2024
	Dietary Supplement Segment			Consulting Service Segment			Total
Revenue from external customers:
Consulting service income	$	–		$	3,838		$	3,838
Sale of dietary supplement products		396,757			–			396,757
Total revenue		396,757			3,838			400,595

Cost of revenue:
Consulting service income		–			–			–
Sale of dietary supplement products		(171,588	)		–			(171,588	)
Total cost of revenue		(171,588	)		–			(171,588	)

Gross profit		225,169			3,838			229,007

Operating Expenses
Selling and distribution		(7,189	)		–			(7,189	)
Personal and benefit costs		(36,462	)		(70,490	)		(106,952	)
General and administrative		(12,967	)		(84,713	)		(97,680	)
Total operating expenses		(56,618	)		(155,203	)		(211,821	)

Segment income (loss)	$	168,551		$	(151,365	)	$	17,186

The below revenues are based on the countries in which the customers are located. Summarized financial information concerning the geographic segments is shown in the following tables:

Schedule of geographic segments
	Three Months ended July 31,
	Three Months ended October 31,				Six Months ended October 31,
	2025		2024		2025		2024
Hong Kong	$	–	$	108,477
China	$	–	$	79,200	$	–	$	79,200
United States of America		103,899		–
Hong Kong		–		92,296		–		200,773
	$	103,899	$	108,477
United States of America		427,115		120,622		531,014		120,622
Total	$	427,115	$	292,118	$	531,014	$	400,595

NOTE 4 － ACCOUNTS RECEIVABLE

Schedule of accounts receivable allowance for credit losses
	July 31, 2025		April 30, 2025
	October 31, 2025		April 30, 2025
Accounts receivable	$	1882,~~014,282~~612	$	1,266,951
Less: allowance for expected credit losses		–		–
Total	$	1882,~~014,282~~612	$	1,266,951

For the three and six months ended ~~July~~October 31, 2025 and 2024, no allowance of expected credit losses was recorded by the Company.

The Company generally conducts its business with creditworthy third parties. The Company determines, on a continuing basis, the probable losses and an allowance for expected credit losses, based on several factors including internal risk ratings, customer credit quality, payment history, historical bad debt/write-off experience and forecasted economic and market conditions. Accounts receivable are written off after exhaustive collection efforts occur and the receivable is deemed uncollectible. In addition, receivable balances are monitored on an ongoing basis and its exposure to bad debts is not significant.

NOTE 5 － INVENTORIES

Inventories comprised of the following:

Schedule of inventories
	July 31, 2025		April 30, 2025
	October 31, 2025		April 30, 2025
Finished goods – Gene Code NR Capsules	$	9,130	$	44,247
Finished goods	$	11,267	$	44,247

For the three and six months ended ~~July~~October 31, 2025 and 2024, no allowance for obsolete inventories was recorded by the Company.

NOTE 6－ INCOME TAX EXPENSE

The income tax provision for the ~~three~~six months ended ~~July~~October 31, 2025 and 2024, consists of the following:

Schedule of income tax provision
	Three Months ended July 31,
	Six Months ended October 31,
	2025		2024
Federal
Current	$	1059,~~585~~357	$	935,~~797~~459
Deferred		–		–2,466
State
Current		317,~~276~~984		–
Deferred		–		–
Income tax provision	$	1377,~~861~~341	$	937,~~797~~925

The deferred tax assets as of ~~July~~October 31, 2025 and April 30, 2025 were $~~120~~147,~~008~~929 and $102,611, respectively, which were fully reserved for valuation allowance. The net change in valuation allowance as of ~~July~~October 31, 2025 and April 30, 2025 was $1745,~~397~~318. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of ~~July~~October 31, 2025 and April 30, 2025. Up to six years since inception remain open for examination only by taxing authorities of US Federal and State of Nevada.

13A reconciliation of the federal income tax rate to the Company’s effective tax rate for the six months ended October 31, 2025 and 2024, consists of the following:

A reconciliation of the federal income tax rate to the Company’s effective tax rate for the three months ended July 31, 2025 and 2024, consists of the following:


	Six months ended October 31,
	2025			2024
Statutory federal income tax rate		21.0%			21.0%
Deferred tax asset		(67.8%	)		(189.3%	)
Change in valuation allowance		67.8%			189.3%
Adjustment to current year taxes		67.8%			189.3%
Effective Tax Rate		88.8%			210.3%

Schedule of reconciliation of income tax rate
	Three months ended July 31,
	2025			2024
Statutory federal income tax rate		21.0%			21.0%
Deferred tax asset		53.6%			42.2%
Change in valuation allowance		(53.6%	)		(42.2%	)
Adjustment to current year taxes		(63.7%	)		(42.6%	)
Effective Tax Rate		(42.7%	)		(21.6%	)

The effective tax rate differs from the statutory tax rate of 21% for the six months ended October 31, 2025 and 2024, primarily due to the adjustment to current year taxes and valuation allowance on the deferred tax assets.

The effective tax rate differs from the statutory tax rate of 21% for the three months ended July 31, 2025 and 2024, primarily due to the adjustment to current year taxes and valuation allowance on the deferred tax assets.15

NOTE 7 － RELATED PARTY BALANCES AND TRANSACTIONS

Nature of relationships with related parties

Name of related party		Relationship with the Company
Qiuping Lu (“Ms. Lu”)		Chief Executive Officer and Director of the Company
Steve Niu (“Mr. Niu”)		Chief Financial Officer of the Company

On January 8, 2024, the Company granted 5,000 ~~common~~ common stocks issuable per month in total of 60,000 common stocks to the Chief Financial Officer - Steve Niu, at fair value of $0.05 per share, subject to vesting condition in completion of one year of service. For the ~~three~~six months ended ~~July~~October 31, 2025 and 2024, the Company ~~recognized~~ recognized share-based compensation in the amount of $Nil and $1,750, respectively. As of ~~July~~October 31, 2025 and April 30, 2025, the Company’s ~~common~~ common stock issuable under share-based compensation totaled $3,000 for 60,000 shares.

NOTE 8 － CONCENTRATIONS OF RISK

The Company is exposed to the following concentrations of risk:

(a)

Cash

The Company maintains cash with banks in the United States of America (“USA”). Should any bank holding cash become insolvent, or if the Company is otherwise unable to withdraw funds, the Company would lose the cash with that bank; however, the Company has not experienced any losses in such accounts and believes it is not exposed to any significant risks on its cash in bank accounts. In the United States, the standard insurance amount is $250,000 per depositor in a bank insured by the Federal Deposit Insurance Corporation (“FDIC”).

Financial instruments that potentially subject the Company to significant concentrations of credit risk are cash. As of ~~July~~October 31, 2025 and April 30, 2025, $~~468~~424,~~926~~210 and $301,267 of the Company’s ~~cash~~ cash held by financial institutions were uninsured, respectively.

1416

(a)	Major customers

For the three and six months ended ~~July~~October 31, 2025, the individual customers who accounted for 10% of the Company’s revenue and its outstanding receivables balance at period-end rates, as presented as follows:

Schedule of concentrations risk
	Three months ended July 31, 2025				As of July 31, 2025
	Three months ended October 31, 2025				As of October 31, 2025
Customer	Revenue		Percentage of revenue		Accounts receivable
Customer A	$	45130,~~000~~050		~~43.~~31.23%	$	–30,050
Customer B		3584,~~630~~520		3420.2930%		–
Customer C		19,043		18.33%		–
Customer D		43,956		10.56%		–
	$	99,673		95.93%	$	–
Total	$	258,526		62.09%	$	30,050


	Six months ended October 31, 2025				As of October 31, 2025
Customer	Revenue		Percentage of revenue		Accounts receivable

Customer A	$	130,050		25.00%	$	30,050
Customer B		120,150		23.09%		–
Customer C		69,991		13.45%		–

Total	$	320,191		61.54%	$	30,050

These customers are located in the United States of America.

~~For the three months ended July 31, 2024, there is one customer who accounted for 100% of the Company’s revenues amounting to $108,477.~~17

~~The customer~~For isthe ~~located~~three inand ~~Hong~~six ~~Kong.~~months ended October 31, 2024, the individual customers who accounted for 10% of the Company’s revenue and its outstanding receivables balance at period-end rates, as presented as follows:


	Three months ended October 31, 2024				As of October 31, 2024
Customer	Revenue		Percentage of revenue		Accounts receivable

Customer E	$	92,296		31.60%	$	–
Customer F		79,200		27.11%		57,700
Customer G		66,668		22.82%		–

Total	$	238,164		81.53%	$	57,700

	Six months ended October 31, 2024				As of October 31, 2024
Customer	Revenue		Percentage of revenue		Accounts receivable

Customer E	$	200,773		50.12%	$	–
Customer F		79,200		19.77%		57,700
Customer G		66,668		16.64%		–

Total	$	346,641		86.53%	$	57,700

These customers are located in Hong Kong, China and the United States of America.

(b)	Major vendors

For the three and six months ended ~~July~~October 31, 2025, there is noone ~~single~~ vendor who accounted for ~~more~~100% ~~than~~and 10100% of the Company’s ~~purchases~~purchase cost amounting to $168,450 and $168,450, respectively.

For the three and six months ended ~~July~~October 31, 2024, there is one vendor who accounted for 54100% and 100% of the Company’s ~~total~~ purchase ~~costs~~cost amounting to $~~114~~210,~~598~~600 and $325,198, respectively.

NOTE 9－ COMMITMENTS AND CONTINGENCIES

As of ~~July~~October 31, 2025, the Company has no commitments or contingencies.

NOTE 10－ SUBSEQUENT EVENTS

In accordance with ASC Topic 855, “Subsequent Events”, which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before the unaudited condensed consolidated financial statements are issued, the Company has evaluated all events or transactions that occurred after ~~July~~October 31, 2025, up to the date that the unaudited condensed consolidated financial statements were available to be be issued.

1519

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our results of operations and financial condition should be read together with our unaudited condensed consolidated financial statements and the notes thereto, which are included elsewhere in this report and our Annual Report on Form 10-K for the fiscal year ended April 30, 2025 (the “Annual Report”) filed with SEC. Our financial statements have been prepared in accordance with U.S. GAAP. In addition, our financial statements and the financial information included in this report reflect our organizational transactions and have been prepared as if our current corporate structure had been in place throughout the relevant periods.

Forward looking statement notice

Statements made in this Form 10-Q that are not ~~historical~~ historical or current facts are “forward-looking statements” made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 ~~(the “Act”)~~ and Section 21E of the Securities Exchange Act of 1934. These statements often can be identified by the use of terms such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” “approximate” or “continue,” or the negative thereof. We intend that such forward-looking statements be subject to the safe harbors for such statements. We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Any forward-looking statements represent management’s best judgment as to what may occur in the future. However, forward-looking statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statement or to reflect the occurrence of anticipated or unanticipated events.

Financial information contained in this report and in our financial statements is stated in United States dollars and are prepared in accordance with United States generally accepted accounting principles.

Corporate Overview

Yijia Group Corp. (“the Company” or “YJGJ”) was incorporated on January 25, 2017 under the laws of the State of Nevada, United States of America, formerly known as Soldino Group Corp.

Meanwhile, the Company continues to look for other opportunities which could potentially increase the profits of the Company in 2025.

Results of Operations

We currently provide business consulting services and market and supply ~~healthcare~~dietary supplement products to domestic and international customers..

The following table sets forth certain operational data for the three and six months ended ~~July~~October 31, 2025 and 2024:

	Three Months Ended July 31,
	Three Months Ended October 31,
	2025			2024
Revenues	$	~~103~~427,~~899~~115		$	~~108~~292,~~477~~118
Cost of revenue		(35166,~~118~~312	)		(35136,~~304~~284	)
Gross profit		68260,~~781~~803			73155,~~173~~834
Total operating expenses		(~~101~~161,~~221~~633	)		(~~118~~93,~~587~~234	)
Loss before income tax		(32,440	)		(45,414	)
Income from operation		99,170			62,600
Income tax expense		(13,861	)		(9,797	)
Other income (expense), net		120			(1,825	)
Net loss	$	(46,301	)	$	(55,211	)
Income before income tax		99,290			60,775
Income tax expense		(63,480	)		(28,128	)
Net income	$	35,810		$	32,647

	Six Months Ended October 31,
	2025			2024
Revenues	$	531,014		$	400,595
Cost of revenue		(201,430	)		(171,588	)
Gross profit		329,584			229,007
Total operating expenses		(262,854	)		(211,821	)
Income from operation		66,730			17,186	)
Other income (expense), net		120			(1,825	)
Income before income tax		66,850			15,361
Income tax expense		(77,341	)		(37,925	)
Net loss	$	(10,491	)	$	(22,564	)

Revenue

For the three and six months ended ~~July~~October 31, 2025, we generated revenues of $427,115 and $531,014, respectively. For the comparative three and six months ended October 31, 2024, we we generated revenues of $~~103~~292,~~899~~118 and $~~108~~400,~~477~~595, respectively. Our major customers are located in Hong Kong, China and the United States of America. Our revenue ~~decreased~~significantly increased by $4134,~~578~~997 and $130,419, or 446% and 33%, respectively due to the commencement of business of the dietary supplement products segment.

During the three ~~ended~~and ~~July~~six months ended October 31, 2025 and 2024, the nature of businesses and segment was shown as below:

Currently, the Company has two reportable business segments:

(i) Consulting Service Segment, mainly provides consulting advisory services in management business, accounting and financial services; and (ii) ~~Healthcare~~Dietary Supplement Segment, mainly provides ~~healthcare~~dietary ~~products~~supplement ~~and~~ healthcare ~~consultation services to the customers~~products.

In the following table, revenue is disaggregated by by primary major product line, including a reconciliation of the disaggregated revenue with the reportable segments. For the three ~~months~~and six months ended ~~July~~October 31, 2025 and 2024, ~~healthcare~~dietary supplement segment did not generate any revenue, and all the revenue was generated from consulting services segment.

	Three Months ended July 31, 2025
	Three Months ended October 31, 2025
	Healthcare Segment			Consulting Service Segment			Total
	Dietary Supplement Segment			Consulting Service Segment			Total
Revenue from external customers:
Consulting service income	$	–		$	46,~~225~~489		$	46,~~225~~489
Sale of healthcare products		99,674			–			99,674
Sale of dietary supplement products		420,626			–			420,626
Total revenue		99420,~~674~~626			~~4,225~~			~~103~~427,~~899~~115
Cost of revenue:
Consulting service income		–			–			–
Sale of healthcare products		(35,118	)		–			(35,118	)
Sale of dietary supplement products		(166,312	)		–			(166,312	)
Total cost of revenue		(35166,~~118~~312	)		–			(35166,~~118~~312	)
Gross profit		64254,~~556~~314			46,~~225~~489			68260,~~781~~803
Operating Expenses
Personal and benefit costs		(11,740	)		(23,188	)		(34,928	)
Sales and distribution expenses		(2,900	)		–			(2,900	)
General and administrative		(2,414	)		(63,879	)		(66,293	)
Personal and benefit costs		(11,739	)		(27,549	)		(39,288	)
Total operating expenses		(14,154	)		(87,067	)		(101,221	)
General and administrative		(7,546	)		(111,899	)		(119,445	)
Segment income (loss)	$	50,402		$	(82,842	)	$	(32,440	)
Total operating expenses		(22,185	)		(139,448	)		(161,633	)
Segment income (loss)	$	232,129		$	(132,959	)	$	99,170

1722

Three Months ended July 31, 2024

Six Months ended October 31, 2025

Healthcare Segment

Consulting Service Segment

Total

Dietary Supplement Segment

Consulting Service Segment

Total

Revenue from external customers:

Consulting service income

–

–10,714

Sale of healthcare products

108,477

–

108,477

Sale of dietary supplement products

520,300

–

520,300

Total revenue

~~108~~520,~~477~~300

–10,714

~~108~~531,~~477~~014

Cost of revenue:

Consulting service income

–

Sale of healthcare products

(35,304

)

–

(35,304

)

Sale of dietary supplement products

(201,430

)

–

(201,430

)

Total cost of revenue

(35201,~~304~~430

)

–

(35201,~~304~~430

)

Gross profit

73318,~~173~~870

–10,714

73329,~~173~~584

Operating Expenses

Selling and distribution

(7,030

)

–

(7,030

)

Sales and distribution expenses

(2,900

)

–

(2,900

)

Personal and benefit costs

(1823,~~739~~479

)

(3550,~~245~~737

)

(5374,~~984~~216

)

General and administrative

(~~751~~9,960

)

(56175,~~822~~778

)

(57185,~~573~~738

)

Total operating expenses

(2636,~~520~~339

)

(92226,~~067~~515

)

(~~118~~262,~~587~~854

)

Segment income (loss)

46282,~~653~~531

(92215,~~067~~801

)

~~(45~~66,~~414~~730

)

	Three Months ended October 31, 2024
	Dietary Supplement Segment			Consulting Service Segment			Total
Revenue from external customers:
Consulting service income	$	–		$	3,838		$	3,838
Sale of dietary supplement products		288,280			–			288,280
Total revenue		288,280			3,838			292,118

Cost of revenue:
Consulting service income		–			–			–
Sale of dietary supplement products		(136,284	)		–			(136,284	)
Total cost of revenue		(136,284	)		–			(136,284	)

Gross profit		151,996			3,838			155,834

Operating Expenses
Selling and distribution		(159	)		–			(159	)
Personal and benefit costs		(17,723	)		(35,245	)		(52,968	)
General and administrative		(12,216	)		(27,891	)		(40,107	)
Total operating expenses		(30,098	)		(63,136	)		(93,234	)

Segment income (loss)	$	121,898		$	(59,298	)	$	62,600

	Six Months ended October 31, 2024
	Dietary Supplement Segment			Consulting Service Segment			Total
Revenue from external customers:
Consulting service income	$	–		$	3,838		$	3,838
Sale of dietary supplement products		396,757			–			396,757
Total revenue		396,757			3,838			400,595

Cost of revenue:
Consulting service income		–			–			–
Sale of dietary supplement products		(171,588	)		–			(171,588	)
Total cost of revenue		(171,588	)		–			(171,588	)

Gross profit		225,169			3,838			229,007

Operating Expenses
Selling and distribution		(7,189	)		–			(7,189	)
Personal and benefit costs		(36,462	)		(70,490	)		(106,952	)
General and administrative		(12,967	)		(84,713	)		(97,680	)
Total operating expenses		(56,618	)		(155,203	)		(211,821	)

Segment income (loss)	$	168,551		$	(151,365	)	$	17,186

The revenues presented below are based on the countries in which the customers are located. Summarized financial information concerning the geographic segments is shown in the following tables:

	Three Months ended July 31,
	Three Months ended October 31,				Six Months ended October 31,
	2025		2024		2025		2024
Hong Kong	$	–	$	108,477
China	$	–	$	79,200	$	–	$	79,200
United States of America		103,899		–
Hong Kong		–		92,296		–		200,773
	$	103,899	$	108,477
United States of America		427,115		120,622		531,014		120,622
Total	$	427,115	$	292,118	$	531,014	$	400,595

Cost of revenue

Cost of revenue as a percentage of net revenue ~~was~~ was approximately 3439% and 3338% for the three and six months ended ~~July~~October 31, 2025, respectively. Cost of revenue as a percentage of net revenue was approximately 47% and 43% for the three and six months ended October 31, 2024, respectively. Cost of revenue ~~decreased~~increased by $30,028 and $~~186~~29,842, or 122% and 17%, respectively.

Gross profit

For the three months ended ~~July~~October 31, 2025 and 2024, the gross profit was $68260,~~781~~803 and $73155,~~173~~834, respectively, and the gross profit margin was 6661% and 6753%, respectively. For the six months ended October 31, 2025 and 2024, the gross profit was $329,584 and $229,007, respectively, and the gross profit margin was 62% and 57%, respectively. The increase in gross profit margin for the periods ended October 31, 2025, compared to the same periods in 2024, is primarily attributable to the more types of dietary supplement products were sold.

Personnel and benefit costs

We incurred personnel and benefit costs of $3439,~~928~~289 and $5352,~~984~~968 for the three months ended ~~July~~October 31, 2025 and 2024, respectively. We incurred personnel and benefit costs of $74,216 and $106,952 for the six months ended October 31, 2025 and 2024, respectively. The decrease in personnel and benefit costs for the periods ended ~~July~~October 31, 2025, compared to the same periods in 2024, is primarily attributable to the decrease in the salaries of key management personnel.

General and administrative expenses

We incurred general and administrative expenses of of $66119,~~293~~444 and $5740,~~573~~107 for the three months ended ~~July~~October 31, 2025 and 2024, respectively. General and administrative expenses increased by by $879,~~721~~337 or 15198% for the three months ended ~~July~~October 31, 2025 compared to the same periods in 2024. We incurred general and administrative expenses of $185,738 and $97,680 for the six months ended October 31, 2025 and 2024, respectively. General and administrative expenses increased by $88,058 or 90% compared to the same period in 2024. The increase in general and administrative expenses is primarily attributable to an increase in legal and professional fees.

Net loss

As a result of the factors described above, we ~~reported~~ reported net ~~loss~~income of $4635,~~301~~810 and $5532,~~211~~647 for the three months ended ~~July~~October 31, 2025 and 2024, respectively. For the six months ended October 31, 2025 and 2024, the Company has a net loss of $10,491 and $22,564, respectively.

Liquidity and capital resources

On ~~July~~October 31, 2025, we had total current assets of $2,~~242~~336,~~358~~244, which consisted primarily of $1,~~046~~259,~~620~~281 in cash, $1882,~~014,282~~612 in accounts receivable, $~~158~~7,~~802~~333 in ~~advances to vendor~~prepayment, $9172,~~130~~ 310 in ~~inventories~~advances to vendor, $1011,~~083~~267 in ~~prepayment~~inventories and $3,441 in other current assets. We had total current liabilities of $~~379~~438,~~975~~051, which consisted of of $67168,~~431~~450 in accounts payable, ~~and~~$68,713 in accrued expenses, $13,~~226~~951 in other current liabilities, $104,~~775~~286 in deferred revenue and $~~300~~192,~~543 in~~651 in income tax payable.

On April 30, 2025, we had total current assets of $2,256,251, which consisted primarily of $782,810 in cash, $1,266,951 in accounts receivable, $158,802 in advances to vendor, $44,247 in inventories and $3,441 in other current assets. We had total current liabilities of $347,567, which consisted of $60,065 in accounts payable and accrued expenses, $820 in other current liabilities and $286,682 in income tax payable.

We have never paid dividends on our Common Stock. Our present policy is to apply cash to investments in product development, acquisitions or expansion; consequently, we do not expect to pay dividends on Common Stock in the foreseeable future.

Cash Flows

The following table sets forth a summary of our cash flows for the periods indicated:

	Three Months ended July 31,
	Six Months ended October 31,
	2025		2024
Net cash provided by (used in) operating activities	$	~~263~~476,~~810~~471	$	(~~504~~495,~~001~~241	)
Net cash provided by financing activities		–		52125,~~600~~000

Operating Activities

For the ~~three~~six months ended ~~July~~October 31, 2025, net cash provided by operating activities was $~~263~~476,~~810~~471 which consisted primarily of a net loss of $4610,~~301~~491, decrease in accounts receivable of $~~252~~384,~~669~~339, decrease in inventories of $3532,~~117~~980, increase in deferred revenue of $104,~~775~~286, increase in other current liabilities of $~~406~~3,131, increase in accounts payable ~~and accrued expenses~~ of $7168,~~366~~450 and ~~increase~~accrued inexpenses ~~income tax payable~~ of $138,~~861~~648. The amounts were partially offset by increase in prepayment of $7,333, increase in advances to vendor of $1013,~~083~~508 and decrease in income tax payable of $94,031.

For the ~~three~~six months ended ~~July~~October 31, 2024, net ~~cash~~ cash used in operating activities was $~~504~~495,~~001~~241 which consisted primarily of a net loss of $5522,~~211~~564, ~~decrease~~increase in ~~inventory~~accounts ofreceivable of $8057,~~590~~700, ~~decrease~~ increase in advances to vendor of $~~379~~210,~~392~~912, ~~and~~increase in inventories of $170,221, decrease in other current liabilities of $67,~~443~~400 and decrease in income tax payable of $39,208. The amounts were partially offset by adjusted non-cash item consisting of share-based compensation of $1,500, interest expense of $~~750~~2,125, ~~increase~~decrease in other current assets of $~~588~~2,638 and increase in accounts payable and accrued expenses of $6,~~500, and increase in income tax payable of $9,797~~501.

Financing Activities

For the ~~three~~six months ended ~~July~~October 31, 2025, net cash provided by financing activities was $0.

For the ~~three~~six months ended ~~July~~October 31, 2024, net ~~cash~~ cash provided by financing activities was $52125,~~600~~000, which consisted primarily of proceed from a ~~director~~related party.

Limited operating history; need for additional capital

There is no historical financial information about us upon which to base an evaluation of our performance. We are in a start-up stage of operations and have generated limited revenues since inception. We cannot guarantee that we will be successful in our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources and possible cost overruns due to price and cost increases in services and products.

Off-Balance Sheet Arrangements

As of ~~July~~ October 31, 2025, the Company did not have any off-balance sheet arrangements that had or were reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Contractual Obligations and Commercial Commitments

We had no contractual obligations and commercial commitments as of ~~July~~ October 31, 2025.

2026

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

None.

ITEM 4.

CONTROLS AND PROCEDURES

Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

An evaluation was conducted under supervision ~~and~~ and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as as of ~~July~~October 31, 2025. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective as as of such date to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms.

The matters involving internal controls and procedures that our management considered to be material weaknesses under the standards of the Public Company Accounting Oversight Board were: (1) lack of a functioning audit committee due to a lack of a majority of independent members and a lack of a majority of outside directors on our Board of Directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures; and (2) ineffective controls over period end financial disclosure and reporting processes. The aforementioned material weaknesses were identified by our Chief Executive Officer and Chief Financial Officer in connection with the review of our financial statements as of ~~July~~October 31, 2025.

Management believes that the material weaknesses set forth above did not have an effect on our financial results. However, management believes that the lack of a functioning audit committee and the lack of a majority of outside directors on our Board of Directors results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in our financial statements in future periods.

To address these material weaknesses, management has initiated steps to strengthen oversight and financial reporting processes, including implementing more formal procedures for preparing and reviewing period-end financial statements and disclosures. We expect that once these measures are fully implemented and operating for a sufficient period, we will remediate the identified weaknesses.

Changes in Internal Controls over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. We are aware that any system of controls, however well designed and operated, can only provide reasonable, and not absolute, assurance that the objectives of the system are met, and that maintenance of disclosure controls and procedures is an ongoing process that may change over time.

2127

PART II – OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

We are not currently a party to any legal proceedings, and we are not aware of any pending or potential legal actions.

ITEM 1A.

RISK FACTORS

The information to be reported under this Item is not required for smaller reporting companies.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.

MINE SAFETY DISCLOSURES

None.

ITEM 5.

OTHER INFORMATION

During the quarter ended ~~July~~October 31, 2025, no ~~director~~ director or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.

ITEM 6.

EXHIBITS

The following exhibits are included as part of this report by reference:

31.1*		Certification of Chief Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a).
31.2*		Certification of Chief Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a).
32.1**		Certification of Chief Executive Officer pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**		Certification of Chief Financial Officer pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith.

** Furnished herewith and not to be incorporated by reference into any filing of Yijia Group Corp. under the Securities Act or the Exchange Act whether made before or after the date of this Quarterly Report.

2228

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, ~~thereunto~~ thereunto duly authorized on ~~September~~December 1215, 2025.

	YIJIA GROUP CORP.


	By:	/s/ Qiuping Lu
		Qiuping Lu, Chief Executive Officer

	By:	/s/ Steve Niu
		Steve Niu, Chief Financial Officer

2329

Filing Compare · VitaNova Life Sciences Corp